XLON
YTT
Market cap2.38bUSD
Apr 20, Last price
14.40GBP
Name
Zhejiang Yongtai Technology Co Ltd
Chart & performance
P/E
—
P/S
0.05
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.02%
Rev. gr., 5y
3.13%
Revenues
5.21b
+13.60%
Net income
-46m
L-90.36%
CFO
-72m
L-35.03%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Yongtai Technology Co., Ltd. engages in the production, research, development, sale, and service of medicines, pesticides, electronic chemicals, and new energy lithium battery materials. Its products include active pharmaceutical ingredients (APIs), pharmaceutical intermediates, advanced intermediates, basic intermediates, pesticides, liquid crystal materials, and lithium battery materials. It also provides contract manufacturing services. The company was founded by Ying Mei Wang and Ren Bao He on October 11, 1999 and is headquartered in Taizhou, China.
Key people
Lijie Chen
Chief Financial Officer, Chief Administrative Officer, Director · since 2014
Youqiao Bai
Deputy General Manager · since 2011
Hui Guan
Secretary of the Board, Deputy General Manager
Jian Rong Luo
Executive Deputy General Manager, Director
Chun Hua Wang
Deputy General Manager, Director · since 2013
Zhihua Zhou
Deputy General Manager · since 2014
Yi Zhong Jin
Deputy General Manager, Director · since 2011
Ying Mei Wang
Chairman of the Board · since 1999
Yuan Liu
Independent Director
Independent Director · since 2013
Fang Zhang
Independent Director · since 2013
Headquarters & legal address
浙江省化学原料药基地临海园区东海第五大道1号
台州市, ZJ 317016
CN
台州市, ZJ 317016
CN
Address
No.1, Donghai 5th Avenue，Zhejiang Provincial Chemical and Medical Raw Materials Base Linhai Zone
Taizhou, ZJ 317016
CN
Taizhou, ZJ 317016
CN
Other language
Zhejiang Yongtai Technology Co., Ltd
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||